Related Experiment Video

Updated: Oct 8, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K

Potential COVID-19 therapeutic approaches targeting angiotensin-converting enzyme 2; An updated review

Saba Zanganeh1, Nima Goodarzi1, Mohammad Doroudian1

  • 1Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Reviews in Medical Virology
|December 27, 2021
PubMed

Insights

Researchers are exploring novel COVID-19 treatments, focusing on angiotensin-converting enzyme II (ACE2) inhibitors. This review details therapeutic strategies like receptor-binding domain inhibitors and microRNAs to combat the SARS-CoV-2 virus.

Area of Science:

  • Virology
  • Pharmacology
  • Biotechnology

Background:

  • COVID-19 presents a global health emergency with significant mortality.
  • Understanding SARS-CoV-2 mechanisms is crucial for developing effective treatments.
  • Angiotensin-converting enzyme II (ACE2) is a key target for therapeutic intervention.

Purpose of the Study:

  • To review published scientific information on potential COVID-19 treatments.
  • To emphasize ACE2 inhibitors as a primary drug target for SARS-CoV-2.
  • To discuss various therapeutic strategies targeting viral entry pathways.

Main Methods:

  • Literature review of scientific publications on COVID-19 treatments.
  • Analysis of therapeutic approaches targeting the ACE2 pathway.
  • Identification and discussion of specific inhibitors and modulators.

Main Results:

  • Several therapeutic strategies targeting ACE2 were identified.
  • SARS-CoV-2 receptor-binding domain (RBD) inhibitors show potential for blocking viral attachment.
  • Human recombinant soluble ACE2 and microRNAs (miRNAs) offer alternative mechanisms to inhibit viral entry.

Conclusions:

  • ACE2 inhibitors represent a promising avenue for COVID-19 treatment development.
  • Targeting viral entry mechanisms, including ACE2/TMPRSS2 expression, is vital.
  • This review provides a foundation for developing advanced therapeutic agents against SARS-CoV-2.
Keywords:
ACE2COVID-19SARS-CoV-2drug repositioningsmall molecule drugs

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.1K

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
883
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
553
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.0K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
1.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
238
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
43